Business
ARIUS recognized for entrepreneurial excellence
Dr. David S. Young awarded "Most Innovative" award by the Association of Chinese Canadian Entrepr...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nDr. David S. Young awarded "Most Innovative" award by the Association\n\n\nof Chinese Canadian Entrepreneurs\n\n\nTORONTO, April 7 /CNW/ - ARIUS Research Inc. (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced that Dr. David S. Young, President and Chief Executive\nOfficer, received the "Most Innovative" award at the Chinese Canadian\nEntrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.\n\n\n"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO\nis the foundation of our company and exemplifies the exceptional innovation\nthat this award honours," said Warren Whitehead, Chief Financial Officer of\nARIUS. "As we transition to a clinical company this year, we are proud that\nARIUS' mission to generate and develop anti-cancer, antibody drugs has been\nrecognized through this honour."\n\n\nThe Chinese Canadian Entrepreneur Awards, sponsored by the Association of\nChinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements\nby business people and entrepreneurs who have strengthened the competitiveness\nof Chinese Canadian business community in the global market. The Most\nInnovative Award is presented to an individual, team of individuals or company\nwho have demonstrated exceptional innovation in their given field and\ncontributed great value to the marketplace.\n\n\nAbout ARIUS\n\n\nARIUS is a biotechnology company discovering and developing the next wave\nof antibody therapeutics. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies and selects\nantibodies based on their functional ability to affect disease. This antibody\ngeneration engine has enabled ARIUS to assemble a portfolio of more than 500\nantibody candidates. In addition to the antibodies it is developing in-house,\nARIUS has ongoing partnerships with key biotechnology and drug development\ncompanies. ARIUS is listed on the TSX under the symbol "ARI". For further\ninformation, visit www.ariusmabs.com.\n\n\nForward-Looking Statements\n\n\nCertain statements in this news release constitute "forward-looking\nstatements" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown ri...